Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

NCT01658501 on ClinicalTrials.gov · last registry update 2015-12-07

An unusually large phase 2: 593 participants, more than double the 110 typical for the stage. Completed July 2013. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: PhaseBio Pharmaceuticals Inc.
Sponsor type: Industry
Enrollment: 593
Started: 2012-07
Primary completion: 2013-07 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Evaluation of dose response of Glymera as measured as the change from baseline in HbA1c after 20 weeks of dosing with Glymera compared to placebo and active comparator

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.